15 December 2022
	
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR
INDIRECTLY, IN OR INTO THE UNITED STATES (INCLUDING ITS TERRITORIES AND
DEPENDENCIES, ANY STATE OF THE UNITED STATES AND THE DISTRICT OF COLUMBIA),
CANADA, AUSTRALIA, NEW ZEALAND, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF
THE PEOPLE'S REPUBLIC OF CHINA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA, OR ANY
OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.
PLEASE SEE "IMPORTANT INFORMATION" AT THE END OF THE PRESS RELEASE.

Benchmark Holdings plc 

("Benchmark", the "Company" or the "Group")

First Day of Trading on Euronext Growth Oslo
Publication of Information Document for Admission on Euronext Growth Oslo 
and Director Appointment

Benchmark Holdings, the aquaculture biotechnology company announces that trading
of its shares on Euronext Growth will commence today. 

The attached information document (the "Information Document") has been prepared
by Benchmark solely for use in connection with the admission to trading of its
shares on Euronext Growth Oslo (the "Admission"). The Information Document has
been made available on the Company's website at
https://www.benchmarkplc.com/investors/oslo-listing/.

The Company has prepared a set of questions & answers ("Q&A") in relation to the
dual-listing on the AIM market of the London Stock Exchange ("AIM") and on
Euronext Growth Oslo, which includes instructions for shareholders on how to
transfer shareholdings between CREST (the electronic settlement system used for
AIM) and VPS (the Norwegian electronic settlement system used for Euronext
Growth Oslo), and how to trade on Euronext Growth Oslo. This Q&A can be found on
the Company's website through the following link:
https://www.benchmarkplc.com/investors/oslo-listing/.

On 30 November 2022, the Company announced the appointment of Laura Lavers as a
Non-Executive Director conditional on the Admission. The Company is pleased to
announce that Laura Lavers' appointment is now effective. Laura Lavers acquired
530,000 shares in the Company in the private placement. Following this purchase
Mrs Lavers holds a total of 530,000 ordinary shares in the Company representing
approximately 0.07% of the issued share capital of the Company